Volume 14, Number 2—February 2008
Dispatch
Prolonged Plasmodium falciparum Infection in Immigrants, Paris
Eric D’Ortenzio*1
, Nadine Godineau†, Arnaud Fontanet‡, Sandrine Houze*, Olivier Bouchaud¶#, Sophie Matheron***, and Jacques Le Bras*
, Nadine Godineau†, Arnaud Fontanet‡, Sandrine Houze*, Olivier Bouchaud¶#, Sophie Matheron***, and Jacques Le Bras*
Table 1
Univariate analysis of factors associated with prolonged Plasmodium falciparum infection in 248 immigrant travelers*
| Variable | Case-patients (n = 61), no. (%) | Controls (n = 197), no. (%) | OR (95% CI) | p value |
|---|---|---|---|---|
| Sex | ||||
| Female | 33 (54.1) | 75 (38.1) | 1 | |
| Male |
28 (45.9) |
122 (61.9) |
0.52 (0.29–0.93) |
0.03 |
| Age, y | ||||
| <5 | 2 (3.3) | 10 (5.1) | 1 | |
| 5–14 | 5 (8.2) | 18 (9.1) | 1.39 (0.22–8.51) | |
| 15–60 | 53 (86.9) | 163 (82.7) | 1.63 (0.34–7.66) | 0.83 |
| >60 |
1 (1.6) |
6 (3.1) |
0.83 (0.06–11.23) |
|
| Origin | ||||
| Sub-Saharan Africa | 55 (90.2) | 181 (91.9) | 1 | |
| Comoros Islands | 5 (8.2) | 14 (7.1) | 1.18 (0.41–3.41) | |
| Other | 1 (1.6) | 2 (1) | 1.65 (0.15–18.5) | 0.89 |
| South America | 0 | 1 (0.5) | NA | |
| Caribbean | 0 | 1 (0.5) | NA | |
| India |
1 (1.6) |
0 |
NA |
|
| First-arrival immigrant | ||||
| No | 24 (39.3) | 183 (92.9) | 1 | |
| Yes |
37 (60.7) |
14 (7.1) |
20.15 (9.54–42.57) |
<0.001 |
| Region of malaria acquisition | ||||
| West Africa | 32 (52.5) | 132 (67) | 1 | |
| Central Africa | 22 (36.1) | 44 (22.3) | 2.06 (1.09–3.92) | 0.03 |
| East Africa | 1 (1.6) | 2 (1) | 2.06 (0.18–23.46) | |
| Comoros Islands | 5 (8.2) | 18 (9.1) | 1.15 (0.4–3.32) | |
| Other |
1 (1.6) |
1 (0.5) |
4.12 (0.25–67.74) |
|
| Chemoprophylaxis | ||||
| No | 50 (82) | 118 (59.9) | 1 | |
| Yes | 9 (14.8) | 71 (36) | 0.3 (0.14–0.65) | 0.002 |
| Unknown |
2 (3.2) |
8 (4.1) |
NA |
|
| Prophylaxis with mefloquine | ||||
| No | 56 (91.8) | 186 (94.4) | 1 | |
| Yes | 3 (4.9) | 3 (1.5) | 3.32 (0.65–16.92) | 0.15 |
| Unknown |
2 (3.3) |
8 (4.1) |
NA |
|
| Antimalarial self-medication | ||||
| No | 55 (90.2) | 171 (86.8) | 1 | |
| Yes | 5 (8.2) | 15 (7.6) | 1.04 (0.36–2.98) | 0.95 |
| Unknown | 1 (1.6) | 11 (5.6) | NA | |
| Men | 28 (45.9) | 122 (61.9) | 1 | |
| Nonpregnant women | 16 (26.2) | 69 (35) | 1.01 (0.51–2) | |
| Pregnant women |
17 (27.9) |
6 (3.1) |
12.35 (4.46–34.14) |
<0.001 |
| HIV status | ||||
| Negative | 22 (36.1) | 42 (21.3) | 1 | |
| Positive | 12 (19.7) | 6 (3.1) | 3.82 (1.26–11.56) | 0.02 |
| Unknown |
27 (44.3) |
149 (75.6) |
NA |
|
| Symptomatic malaria | ||||
| No | 8 (13.1) | 0 (0) | 1 | |
| Yes |
53 (86.9) |
197 (100) |
0.3 (0.25–0.47) |
<0.001 |
| Parasitemia† | ||||
| High | 2 (3.3) | 18 (9.1) | 1 | |
| Low | 59 (96.7) | 179 (90.9) | 1.61 (0.53–4.9) | 0.4 |
*OR, odds ratio; CI, confidence interval; NA, not applicable.
†Parasitemia (parasitized erythrocytes) was considered high if >4% and low if <4% by World Health Organization criteria.
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.